Michael Richman
Vermögen: 220 224 $ am 31.05.2026
Vermögen: 220 224 $ am 31.05.2026
Mr. Michael S.
Richman is a President, Chief Executive Officer & Director at NextCure, Inc. He is on the Board of Directors at NextCure, Inc. Mr. Richman was previously employed as a Chairman by GenVec, Inc., an Independent Director by Pieris Pharmaceuticals, Inc., a Member-Supervisory Board by Pieris AG, a President & Chief Executive Officer by Amplimmune, Inc., an Independent Director by Opexa Therapeutics, Inc., a Chief Operating Officer & Executive Vice President by MacroGenics, Inc., a SVP-Corporate Development & Administration by MedImmune LLC, and a Director-Corporate Business Development by Chiron Corp.
He also served on the board at Madison Vaccines, Inc., PharmaFrontiers Corp., Cougar Biotechnology, Inc. and Cougar Biotechnology, Inc. /Old/.
He received his undergraduate degree from the University of California, Davis and a graduate degree from San Francisco State University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NEXTCURE, INC. 1,33 % | 22.04.2026 | 35.520 ( 1,33 % ) | 220 224 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| NEXTCURE, INC. | Gründer | 01.12.2015 |
| Unternehmen | Position | Ende |
|---|---|---|
| PIERIS PHARMACEUTICALS | Direktor/Vorstandsmitglied | 13.12.2024 |
Madison Vaccines, Inc.
Madison Vaccines, Inc. Pharmaceuticals: MajorHealth Technology Develops vaccines for patients with prostate cancer | Direktor/Vorstandsmitglied | 01.01.2024 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops autologous personalized cell therapies for the treatment of various diseases. | Direktor/Vorstandsmitglied | 19.09.2017 |
| GENVEC INC | Vorsitzender | 16.06.2017 |
Amplimmune, Inc.
Amplimmune, Inc. BiotechnologyHealth Technology Develops immune-based biological treatments | Vorstandsvorsitzender | 01.07.2015 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 15 |
|---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
MedImmune LLC
MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
GenVec, Inc.
GenVec, Inc. Pharmaceuticals: MajorHealth Technology Develops bio-pharmaceutical products | Health Technology |
Cougar Biotechnology, Inc. /Old/
Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Health Technology |
Amplimmune, Inc.
Amplimmune, Inc. BiotechnologyHealth Technology Develops immune-based biological treatments | Health Technology |
MacroGenics, Inc.
MacroGenics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes antibody-based therapeutics for the treatment of cancer | Health Technology |
PharmaFrontiers Corp.
PharmaFrontiers Corp. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
San Francisco State University
San Francisco State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Davis
University of California, Davis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pieris AG
Pieris AG BiotechnologyHealth Technology Develops and markets an Anticalin-brand protein technology | Health Technology |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops autologous personalized cell therapies for the treatment of various diseases. | Health Technology |
Janssen Oncology, Inc.
Janssen Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Health Technology |
Madison Vaccines, Inc.
Madison Vaccines, Inc. Pharmaceuticals: MajorHealth Technology Develops vaccines for patients with prostate cancer | Health Technology |
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and markets an anticalin-brand protein technology | Health Technology |
NextCure, Inc.
NextCure, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which discovers and develops novel immuno medicines to treat cancer & immune related diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen